Evidence map›Paper›PMID 23175674›Full record

Trial reportArteriosclerosis, thrombosis, and vascular biology2013

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.

Aramesh Saremi, Dawn C Schwenke, Thomas A Buchanan, Howard N Hodis, Wendy J Mack, Maryann Banerji, George A Bray, Stephen C Clement, Robert R Henry, Abbas E Kitabchi and 7 more

Erratum issuedOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arteriosclerosis, thrombosis, and vascular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 6 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pharmacological interventions for asymptomatic carotid stenosis.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.The New England journal of medicine · 2016 · on this map
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Review
  19. Observational
  20. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Aramesh SaremiPhoenix Veterans Affair (VA) Health Care System, Phoenix, AZ, USA.
Dawn C Schwenke
Thomas A Buchanan
Howard N Hodis
Wendy J Mack
Maryann Banerji
George A Bray
Stephen C Clement
Robert R Henry
Abbas E Kitabchi
Sunder Mudaliar
Robert E Ratner
Frankie B Stentz
Nicolas Musi
Devjit Tripathy
Ralph A DeFronzo
Peter D Reaven
Georgetown University · USMedStar Health · USSUNY Downstate Health Sciences University · USThe University of Texas Health Science Center at San Antonio · USUniversity of San Diego · USUniversity of Tennessee Health Science Center · USLouisiana State University · USPennington Biomedical Research Center · USUC San Diego Health System · US

Funding

LOS ANGELES BASIN CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR031986 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2010 to 2011
$21.1M
NCRR NIH HHS UL1 RR031986
6 · The paper itself

Abstract

objectiveTo determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes. METHODS AND

resultsCIMT was measured in 382 participants at the beginning and up to 3 additional times during follow-up of the Actos Now for Prevention of Diabetes trial. During an average follow-up of 2.3 years, the mean unadjusted annual rate of CIMT progression was significantly (P=0.01) lower with pioglitazone treatment (4.76×10(-3) mm/year; 95% CI: 2.39×10(-3)-7.14×10(-3) mm/year) compared with placebo (9.69×10(-3) mm/year; 95% CI: 7.24×10(-3)-12.15×10(-3) mm/year). High-density lipoprotein cholesterol, fasting and 2-hour glucose, HbA(1c), fasting insulin, Matsuda insulin sensitivity index, adiponectin, and plasminogen activator inhibitor-1 levels improved significantly with pioglitazone treatment compared with placebo (P<0.001). However, the effect of pioglitazone on CIMT progression was not attenuated by multiple methods of adjustment for traditional, metabolic, and inflammatory risk factors and concomitant medications, and was independent of changes in risk factors during pioglitazone treatment.

conclusionsPioglitazone slowed progression of CIMT, independent of improvement in hyperglycemia, insulin resistance, dyslipidemia, and systemic inflammation in prediabetes. These results suggest a possible direct vascular benefit of pioglitazone.

Indexed as

AdiponectinAdultAgedBiomarkersBlood GlucoseCarotid Artery DiseasesCarotid Intima-Media ThicknessChi-Square DistributionCholesterol, HDLDiabetes Mellitus, Type 2Disease ProgressionDouble-Blind MethodFemaleGlycated HemoglobinHumansHypoglycemic AgentsAdiponectinADIPOQ protein, humanBiomarkersBlood GlucoseCholesterol, HDLGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinPioglitazonePlasminogen Activator Inhibitor 1SERPINE1 protein, humanThiazolidinediones

Identifiers

PMID23175674
PMCPMC3908828
OpenAlexW2093794516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.